Karel Eechoute

1.3k total citations
22 papers, 985 citations indexed

About

Karel Eechoute is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, Karel Eechoute has authored 22 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 8 papers in Hematology. Recurrent topics in Karel Eechoute's work include Gastrointestinal Tumor Research and Treatment (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Karel Eechoute is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Karel Eechoute collaborates with scholars based in Netherlands, United States and Australia. Karel Eechoute's co-authors include Ron H.J. Mathijssen, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, Herman Burger, John B.A.G. Haanen, Henk‐Jan Guchelaar, Judith A.M. Wessels, Hans Gelderblom and Nielka P. van Erp and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Karel Eechoute

22 papers receiving 972 citations

Peers

Countries citing papers authored by Karel Eechoute

Since Specialization

Citations

This map shows the geographic impact of Karel Eechoute's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karel Eechoute with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karel Eechoute more than expected).

Fields of papers citing papers by Karel Eechoute

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karel Eechoute. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karel Eechoute. The network helps show where Karel Eechoute may publish in the future.

Co-authorship network of co-authors of Karel Eechoute

This figure shows the co-authorship network connecting the top 25 collaborators of Karel Eechoute. A scholar is included among the top collaborators of Karel Eechoute based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karel Eechoute. Karel Eechoute is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation 2022 ·Hepatology Communications ·C. Louwrens Braal, Robert J. de Knegt, Agnes Jager, Stijn L.W. Koolen, Ron H.J. Mathijssen, Karel Eechoute	2
2	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib 2020 ·Pharmaceutics ·Koen G. A. M. Hussaarts, Leni van Doorn, Karel Eechoute, Jeffrey Damman, Qiang Fu, (unknown), Eric D. Eisenmann, Alice A. Gibson, Esther Oomen‐de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L.W. Koolen, Teun van Gelder, Roelof W. F. van Leeuwen, Ron H.J. Mathijssen, Alex Sparreboom, Sander Bins	10
3	Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment 2016 ·European Journal of Cancer ·Jacqueline S. L. Kloth, Paul Hamberg, (unknown), R. R. Dulfer, Bronno van der Holt, Karel Eechoute, Erik A.C. Wiemer, Wim H.J. Kruit, Stefan Sleijfer, Ron H.J. Mathijssen	15
4	Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure 2016 ·Clinical Pharmacokinetics ·Sander Bins, Karel Eechoute, Jacqueline S. L. Kloth, Femke M. de Man, (unknown), Peter de Bruijn, Stefan Sleijfer, Ron H.J. Mathijssen	12
5	Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study 2013 ·Clinical Pharmacokinetics ·Jacqueline S. L. Kloth, Heinz‐Josef Klümpen, Huixin Yu, Karel Eechoute, Caroline Samer, Boen L.R. Kam, Alwin D. R. Huitema, Youssef Daali, Aeilko H. Zwinderman, Bavanthi Balakrishnar, Roelof J. Bennink, Mark Wong, Jan H.M. Schellens, Ron H.J. Mathijssen, Howard Gurney	22
6	Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients 2013 ·PLoS ONE ·Gaia Schiavon, Alessandro Ruggiero, (unknown), Bronno van der Holt, (unknown), Karel Eechoute, (unknown), Gabriël P. Krestin, Jaap Verweij, Stefan Sleijfer, Ron H.J. Mathijssen	2
7	A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients 2012 ·Clinical Cancer Research ·Karel Eechoute, Martin N. Fransson, (unknown), Floris A. de Jong, Alex Sparreboom, Winette T.A. van der Graaf, Lena E. Friberg, Gaia Schiavon, Erik A.C. Wiemer, Jaap Verweij, Walter J. Loos, Ron H.J. Mathijssen, Ugo De Giorgi	87
8	Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension 2012 ·Clinical Pharmacology & Therapeutics ·Karel Eechoute, Astrid A.M. van der Veldt, Sjoukje F. Oosting, Mariëtte H.W. Kappers, Judith A.M. Wessels, Hans Gelderblom, Henk‐Jan Guchelaar, A.K.L. Reyners, Carla M.L. van Herpen, John B.A.G. Haanen, Ron H.J. Mathijssen, Epie Boven	72
9	Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients 2012 ·PLoS ONE ·Gaia Schiavon, Alessandro Ruggiero, Patrick Schöffski, Bronno van der Holt, (unknown), Karel Eechoute, Vincent Vandecaveye, Gabriël P. Krestin, Jaap Verweij, Stefan Sleijfer, Ron H.J. Mathijssen	37
10	Drug transporters of platinum-based anticancer agents and their clinical significance 2011 ·Drug Resistance Updates ·Herman Burger, Walter J. Loos, Karel Eechoute, Jaap Verweij, Ron H.J. Mathijssen, Erik A.C. Wiemer	194
11	Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 2011 ·Clinical Pharmacology & Therapeutics ·Karel Eechoute, Ryan M. Franke, Walter J. Loos, (unknown), (unknown), Jaap Verweij, Howard Gurney, R B Kim, Rommel G. Tirona, Ron H.J. Mathijssen, Alex Sparreboom	40
12	Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression 2011 ·The Journal of Clinical Endocrinology & Metabolism ·Mariëtte H.W. Kappers, Joep H.M. van Esch, Frank Smedts, Ronald R. de Krijger, Karel Eechoute, Ron H.J. Mathijssen, Stefan Sleijfer, Frank Leijten, A.H. Jan Danser, Anton H. van den Meiracker, Theo J. Visser	79
13	Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study. 2011 ·Journal of Clinical Oncology ·Karel Eechoute, Martin N. Fransson, Ugo De Giorgi, Anna K.L. Reyners, Floris A. de Jong, Lena E. Friberg, Winette T.A. van der Graaf, Alex Sparreboom, Jaco J. Verweij, Walter J. Loos, Ron H.J. Mathijssen	3
14	Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM). 2011 ·Journal of Clinical Oncology ·Gaia Schiavon, (unknown), Stefan Sleijfer, Karel Eechoute, G. P. Krestin, Jaco J. Verweij, Ron H.J. Mathijssen	1
15	Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib 2010 ·Clinical Cancer Research ·Astrid A.M. van der Veldt, Karel Eechoute, Hans Gelderblom, Jourik A. Gietema, Henk‐Jan Guchelaar, Nielka P. van Erp, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Ron H.J. Mathijssen, Judith A.M. Wessels	127
16	Suppressing Effects of Sunitinib on Allergic Rhinitis: Previously Undefined Side Effects With Therapeutic Potential 2010 ·The Journal of Clinical Pharmacology ·Karel Eechoute, Monika van Zonneveld, Paul Van Daele, Roy Gerth van Wijk, Ron H.J. Mathijssen	2
17	Drug Transporters and Imatinib Treatment: Implications for Clinical Practice 2010 ·Clinical Cancer Research ·Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, Ron H.J. Mathijssen	128
18	Pharmacogenetic factors predicting the need for a higher dose of imatinib. 2010 ·Journal of Clinical Oncology ·Heinz‐Josef Klümpen, Karel Eechoute, Mark Hertzberg, (unknown), David Goldstein, Timothy P. Hughes, Chris Liddle, Ron H.J. Mathijssen, Jan H.M. Schellens, Howard Gurney	1
19	Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib. 2010 ·Journal of Clinical Oncology ·Karel Eechoute, (unknown), Hans Gelderblom, Jourik A. Gietema, Henk‐Jan Guchelaar, (unknown), E. Boven, John B.A.G. Haanen, Ron H.J. Mathijssen, J. Wessels	1
20	Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity 2009 ·Journal of Clinical Oncology ·Nielka P. van Erp, Karel Eechoute, (unknown), John B.A.G. Haanen, A.K.L. Reyners, Ron H.J. Mathijssen, Epie Boven, Tahar van der Straaten, Renée Baak-Pablo, Judith A.M. Wessels, Henk‐Jan Guchelaar, Hans Gelderblom	144

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact